Pay in 4 interest-free payments of $6.45 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Research Highlights: The weight loss medication tirzepatide significantly lowered the systolic blood pressure of nearly 500 adults who had obesity and took the medication for 36 weeks, or about eight months, in a subset of an international clinical trial
PMID: 40691175 Nat Commun 2022 Jun 17;13(1):3486
The interactions of oxyntomodulin differed, with more transient contacts deep within the peptide binding cavity and with residues along the peptide exposed face of TM2, ECL1 and ECL2
The peptide appeared to induce activation of ribosomal genes and decondensation of the heterochromatin
:max_bytes(150000):strip_icc()/GettyImages-1807240274-2c7c39cb23f34a97bb2d8620911c343d.jpg)
US$ 25.08
US$ 20.11
US$ 20.06
